Literature DB >> 20074533

Will iPS cells enhance therapeutic applicability of cord blood cells and banking?

Hal E Broxmeyer1.   

Abstract

The exciting development of induced pluripotent stem cells (iPSCs), and the discovery that iPSCs can be derived from cord blood (CB), combined with the presence of nonhematopoietic stem and progenitor cells in CB may lead to enhanced therapeutic applicability of this cell source and induce increased CB banking. Copyright 2010 Elsevier Inc. All rights reserved.

Mesh：

Year:  2010        PMID： 20074533     DOI： 10.1016/j.stem.2009.12.008

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  18 in total

1.  Pilot social feasibility study for the establishment of a public human umbilical cord blood stem cell bank in South Africa.

Authors:  Madelein Meissner-Roloff; Wendy Young; Isabella Rangaka; Hennie Lombaard; Ames Dhai; Norma Tsotsi; Michael S Pepper
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

Review 2.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

Review 3.  Insights into the biology of cord blood stem/progenitor cells.

Authors:  H E Broxmeyer
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

4.  Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood.

Authors:  Hal E Broxmeyer; Man-Ryul Lee; Giao Hangoc; Scott Cooper; Nutan Prasain; Young-June Kim; Coleen Mallett; Zhaohui Ye; Scott Witting; Kenneth Cornetta; Linzhao Cheng; Mervin C Yoder
Journal:  Blood       Date:  2011-03-10       Impact factor: 22.113

5.  Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and efficacy of nonhomologous end-joining.

Authors:  Jinshui Fan; Carine Robert; Yoon-Young Jang; Hua Liu; Saul Sharkis; Stephen Bruce Baylin; Feyruz Virgilia Rassool
Journal:  Mutat Res       Date:  2011-06-28       Impact factor: 2.433

6.  Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone.

Authors:  Xianmei Meng; Amanda Neises; Rui-Jun Su; Kimberly J Payne; Linda Ritter; Daila S Gridley; Jun Wang; Matilda Sheng; K-H William Lau; David J Baylink; Xiao-Bing Zhang
Journal:  Mol Ther       Date:  2011-11-22       Impact factor: 11.454

Review 7.  Do we still need human embryonic stem cells for stem cell-based therapies? Epistemic and ethical aspects.

Authors:  Kristina Hug; Göran Hermerén
Journal:  Stem Cell Rev Rep       Date:  2011-11       Impact factor: 5.739

8.  Epigenetic regulation of NANOG by miR-302 cluster-MBD2 completes induced pluripotent stem cell reprogramming.

Authors:  Man Ryul Lee; Nutan Prasain; Hee-Don Chae; Young-June Kim; Charlie Mantel; Mervin C Yoder; Hal E Broxmeyer
Journal:  Stem Cells       Date:  2013-04       Impact factor: 6.277

Review 9.  Umbilical cord blood transplantation: the first 25 years and beyond.

Authors:  Karen K Ballen; Eliane Gluckman; Hal E Broxmeyer
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

Review 10.  Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types.

Authors:  Xuan Ou; Heather A O'Leary; Hal E Broxmeyer
Journal:  Blood       Date:  2013-05-01       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.